Journal article
Effectiveness of an mRNA vaccine booster dose against COVID-19 among U.S. healthcare personnel, October 2021–July 2022
Open forum infectious diseases, Vol.10(10), pp.1-10
09/30/2023
DOI: 10.1093/ofid/ofad457
PMCID: PMC10549208
PMID: 37799130
Abstract
Abstract Background Protection against symptomatic SARS-CoV-2 infection (COVID-19) can limit transmission and the risk of post-COVID conditions, and is particularly important among healthcare personnel. However, lower vaccine effectiveness (VE) has been reported since predominance of the Omicron SARS-CoV-2 variant. Methods We evaluated VE of a monovalent mRNA booster dose against COVID-19 during October 2021–June 2022 among U.S. healthcare personnel. After matching case-participants with COVID-19 to control-participants by two-week period and site, we used conditional logistic regression to estimate VE of a booster dose compared with completing only two mRNA doses >150 days previously, adjusted for multiple covariates. Results Among 3,279 case-participants and 3,998 control-participants who had completed two mRNA doses, we estimated that VE of a booster dose against COVID-19 declined from 86% (95% confidence interval [CI], 81%–90%) during Delta predominance to 65% (95% CI, 58%–70%) during Omicron predominance. During Omicron predominance, VE declined from 73% (95% CI, 67%–79%) 14–60 days after the booster dose, to 32% (4%–52%) 120 days or more after a booster dose. We found that VE was similar by age group, presence of underlying health conditions, pregnancy status on the test date, and among immunocompromised participants. Conclusions A booster dose conferred substantial protection against COVID-19 among healthcare personnel. However, effectiveness was lower during Omicron predominance, and waning effectiveness was observed four months after booster dose receipt during this period. Our findings support recommendations to stay up-to-date on recommended doses of COVID-19 vaccines for all those eligible.
Details
- Title: Subtitle
- Effectiveness of an mRNA vaccine booster dose against COVID-19 among U.S. healthcare personnel, October 2021–July 2022
- Creators
- Ian D Plumb - National Center for Immunization and Respiratory DiseasesNicholas M Mohr - University of IowaMelissa Hagen - National Center for Immunization and Respiratory DiseasesRyan Wiegand - National Center for Immunization and Respiratory DiseasesGhinwa Dumyati - University of Rochester Medical CenterKarisa K Harland - University of IowaAnusha Krishnadasan - Education and Research InstituteJade James GistGlen Abedi - National Center for Immunization and Respiratory DiseasesKatherine E Fleming-Dutra - National Center for Immunization and Respiratory DiseasesNora Chea - National Center for Emerging and Zoonotic Infectious DiseasesJane LeeDevra Barter - Colorado Department of Public Health and EnvironmentMonica BrackneyScott F FridkinLucy E Wilson - Maryland Department of HealthSara A Lovett - Minnesota Department of HealthValerie Ocampo - Oregon Health AuthorityErin C Phipps - University of New MexicoTiffanie M MarcusHoward A Smithline - Baystate Medical CenterPeter C Hou - Brigham and Women's HospitalLilly C Lee - Jackson Memorial HospitalGregory J MoranElizabeth Krebs - Thomas Jefferson University HospitalMark T Steele - University of Missouri–Kansas CityStephen C Lim - University Medical Center New OrleansWalter A Schrading - University of Alabama at BirminghamBrian Chinnock - University of California, San FranciscoDavid G Beiser - University of ChicagoBrett Faine - University of IowaJohn P Haran - University of Massachusetts Chan Medical SchoolUtsav Nandi - University of Mississippi Medical CenterAnne K Chipman - University of WashingtonFrank LoVecchio - HealthwiseDavid A TalanTamara Pilishvili - National Center for Immunization and Respiratory Diseases
- Resource Type
- Journal article
- Publication Details
- Open forum infectious diseases, Vol.10(10), pp.1-10
- DOI
- 10.1093/ofid/ofad457
- PMID
- 37799130
- PMCID
- PMC10549208
- NLM abbreviation
- Open Forum Infect Dis
- ISSN
- 2328-8957
- eISSN
- 2328-8957
- Grant note
- DOI: 10.13039/100000030, name: Centers for Disease Control and Prevention, award: U01CK000480; name: Institute for Clinical and Translational Science; DOI: 10.13039/100008893, name: University of Iowa; DOI: 10.13039/100006108, name: National Center for Advancing Translational Sciences; DOI: 10.13039/100000002, name: National Institutes of Health, award: UL1TR002537
- Language
- English
- Electronic publication date
- 09/08/2023
- Date published
- 09/30/2023
- Academic Unit
- Epidemiology; Emergency Medicine; Pharmacy Practice and Science; Anesthesia; Injury Prevention Research Center; Law Faculty; Internal Medicine
- Record Identifier
- 9984464478102771
Metrics
11 Record Views